Learn about LUCENTIS & how it may help with myopic CNV (mCNV) symptoms

LUCENTIS is a prescription medicine approved to treat myopic CNV (mCNV) in 2017.  It is designed to block a protein inside the eye called VEGF (vej-EFF), or vascular endothelial (VASS-cue-ler end-oh-THEEL-e-ull) growth factor.

Click on the links below to read about the role of VEGF, and how LUCENTIS may help if you have myopic choroidal neovascularization (mCNV).

What is VEGF? What does it have to do with mCNV?

In the healthy eye, a protein called vascular endothelial growth factor, or VEGF, helps grow new blood vessels.

  • In eyes with mCNV, there may be too much VEGF. This leads to the abnormal blood vessel growth that can cause vision problems

What is visual acuity?

Your doctor can detect changes or problems in your vision with a visual acuity test. Visual acuity tests find the smallest letters you can see on a standard eye chart. Visual acuity is the sharpness of your vision.

  • The farther down an eye chart you can see, the higher your visual acuity
  • Seeing more eye chart letters than before means that vision is getting better
  • Seeing fewer eye chart letters than before means that vision is getting worse

Visual acuity is expressed as a fraction such as 20/40 or a single number such as 1.5. 

  • The larger the bottom number in the fraction or the higher the single number, the less sharp your vision is

Following up with your doctor is necessary for tracking your vision over time.

How may LUCENTIS help people with mCNV?

LUCENTIS may help people with mCNV see more letters on an eye chart

In a 3-month study of 276 people with mCNV:

  • 2 groups of patients received LUCENTIS (222 patients total), and 55 patients did not receive LUCENTIS

LUCENTIS may help improve* vision in people with mCNV

*Improvement is defined as the ability to see 15 or more letters on an eye chart.

 

In the same 3-month study:

How often will I need a LUCENTIS treatment?

Your doctor will decide how often you need LUCENTIS treatments. Monthly treatments are recommended for up to 3 months.

  • In a study of 222 patients treated with LUCENTIS, 2 out of 5 people (41%) with mCNV had 1, 2, or 3 injections over the course of 3 months and received no injections thereafter.

 

If you think you are experiencing problems with vision from mCNV or sudden vision loss, make an appointment with a Retina Specialist right away.

If you do not have a Retina Specialist, ask your primary care physician or ophthalmologist about a referral.

Learn what you may expect for your LUCENTIS treatment